Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real‐life practice

Hua Zhang, Calvin Q. Pan, Qiumei Pang, Ruihua Tian, Miaoe Yan, Xin Liu – 27 January 2014 – Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother‐to‐child transmission (MTCT) in real‐world settings. During the period of January 2009 to March 2011, we enrolled hepatitis B e antigen–positive mothers with HBV DNA >6 log10 copies/mL in China. At gestation week 28, the mothers received LdT or LAM until postpartum week 4 or no treatment (NTx). The study endpoints were the safety of LdT/LAM use and MTCT rates.

Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real‐life practice

Hua Zhang, Calvin Q. Pan, Qiumei Pang, Ruihua Tian, Miaoe Yan, Xin Liu – 27 January 2014 – Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother‐to‐child transmission (MTCT) in real‐world settings. During the period of January 2009 to March 2011, we enrolled hepatitis B e antigen–positive mothers with HBV DNA >6 log10 copies/mL in China. At gestation week 28, the mothers received LdT or LAM until postpartum week 4 or no treatment (NTx). The study endpoints were the safety of LdT/LAM use and MTCT rates.

Functional genomics identified a novel protein tyrosine phosphatase receptor type f‐mediated growth inhibition in hepatocarcinogenesis

Rabindranath Bera, Chih‐Yung Chiou, Ming‐Chin Yu, Jei‐Ming Peng, Chung‐Ru He, Chih‐Yun Hsu, Hsiao‐Ling Huang, Uda Y. Ho, Shi‐Ming Lin, Yu‐Jr Lin, Sen‐Yung Hsieh – 27 January 2014 – It is unclear how proliferating cells elicit suppression on cell proliferation and how cancer cells evade this growth suppression.

Antibody‐mediated rejection in liver transplantation: Current controversies and future directions

Timucin Taner, Mark D. Stegall, Julie K. Heimbach – 27 January 2014 – Interest in the role of donor‐specific human leukocyte antibodies in liver transplantation has been rekindled recently. Emerging evidence suggests that these antibodies may cause injury to the liver allograft. Here we review the clinical literature, highlight controversial results, and propose a path forward for the definition and better understanding of antibody‐mediated injury to the liver. Liver Transpl 20:514–527, 2014. © 2014 AASLD.

Duct‐to‐duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy

Michael E. Sutton, Rico D. Bense, Ton Lisman, Eric J. Jagt, Aad P. Berg, Robert J. Porte – 24 January 2014 – There is no consensus on the preferred type of biliary reconstruction for patients undergoing orthotopic liver transplantation (OLT) for primary sclerosing cholangitis (PSC). The aim of this study was to compare long‐term outcomes after OLT for PSC using either duct‐to‐duct anastomosis or Roux‐en‐Y hepaticojejunostomy for biliary reconstruction.

Subscribe to